<DOC>
	<DOCNO>NCT00880854</DOCNO>
	<brief_summary>The purpose study find high safe dose investigational drug CP-675,206 give combination BCG therapy patient experience recurrent superficial bladder cancer standard BCG treatment . In addition , study look see take CP 675,206 generates immune response evaluate drug affect superficial bladder cancer .</brief_summary>
	<brief_title>Study CP-675,206 Bacillus Calmette-Guerin ( BCG ) -Resistant Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis transitional cell cancer bladder must complete transurethral resection visible bladder tumor , complete two previous 6week course intravesical BCG . Evidence disease recurrence within 1 year previous BCG treatment Tumor tissue must available biopsy study relate immunohistochemical analysis If sexually active must use reliable form contraception study 4 week last treatment ECOG performance status &lt; 2 Life expectancy least 6 month Adequate hematologic , renal liver function Informed consent No evidence immunosuppression treat immunosuppressive therapy within 6 month No prior radiation pelvis No gross hematuria within 1 week prior plan week 1 treatment Can previous intolerance BCG Can seropositive HIV , hepatitis B ( HBV ) hepatitis C ( HCV ) per patient history No evidence metastatic disease No prior treatment antiCTLA4 monoclonal antibody Can pregnant lactate No history autoimmune disorder No history thyroid adrenal insufficiency No history inflammatory bowel condition , include diverticulitis , ulcerative colitis , Crohn 's celiac disease , intractable urinary tract infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>BCG-resistant localized transitional cell bladder</keyword>
</DOC>